regeneron semaglutide (REGN) Highlights Benefits of and Trevogrumab in Obesity Management Semaglutide GLP-1 Receptor Agonist Research

When a decision is to be made on whether someone should get started on [medication] or not, so I feel like this [study] will be very helpful concerning those discussions. We are building evidence that hopefully can be built into prediction models to help patients estimate, based on their individual circumstances, what is the most likely range of weight reduction given their persistence, BMI, sex, medication they are about to start at the time of decision-making on which GLP-1 medication to choose, or whether to choose pharmacotherapy or another modality for the treatment of obesity, Gasoyan said

If the pen still wont dispense, check for blockages or issues with the needle

Jin, H., Li, M., Jeong, E., Castro-Martinez, F

There may also be some placebo effects here, just from trying to be better in general

European cost-effectiveness bodies updated modeling frameworks in 2025 to credit cardiovascular benefit, tilting decisions toward semaglutide for secondary prevention